person · Reporting owner
MARTIN WILLIAM E. III
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Azenta, Inc.AZTA · Entity 4724 | President Multiomics | September 14, 2026 | September 17, 2026 |
| MARAVAI LIFESCIENCES HOLDINGS, INC.MRVI · Entity 4291 | Chief Executive Officer | March 17, 2025 | March 19, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Azenta, Inc.
Report date September 14, 2026 · Filed September 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| CommonSEC Table I · non-derivative | Direct | 33,062 |
Reported balance
After 2026-09-14 transaction · row 1
1 source rowRow 1 · 2026-09-14 · Grant · Acquired 15,272 · Balance 33,062 F1: Grant of restricted stock units to the Reporting Person under the Company's Equity Incentive Plan. No amount was paid upon grant of the units. Because the units are payable solely in shares of common stock, they are reported in Table I of this Form 4. The units are subject to time-based vesting and will vest 50% per year, beginning on September 14, 2027, subject to the terms of the award agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of restricted stock units to the Reporting Person under the Company's Equity Incentive Plan. No amount was paid upon grant of the units. Because the units are payable solely in shares of common stock, they are reported in Table I of this Form 4. The units are subject to time-based vesting and will vest 50% per year, beginning on September 14, 2027, subject to the terms of the award agreement.
MARAVAI LIFESCIENCES HOLDINGS, INC.
Report date March 17, 2025 · Filed March 19, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 1,814,643 |
Reported balance
After 2025-03-17 transaction · row 1
1 source rowRow 1 · 2025-03-17 · Grant · Acquired 986,194 · Balance 1,814,643 F1: Represents restricted stock units ("RSUs") awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan. Each RSU represents the right to receive one share of Class A Common Stock of the Issuer upon vesting. The RSUs will vest in 1/3rd increments on each of March 15, 2026, March 15, 2027, and March 15, 2028, subject to the Reporting Person's continued employment with the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs") awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan. Each RSU represents the right to receive one share of Class A Common Stock of the Issuer upon vesting. The RSUs will vest in 1/3rd increments on each of March 15, 2026, March 15, 2027, and March 15, 2028, subject to the Reporting Person's continued employment with the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 14, 2026 Filed Sep 17, 2026 00:25 UTC | Azenta, Inc. AZTA · Entity 4724 | GrantCommon | 15,272 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-062348 · wk-form4_1789604730.xml · nonDerivative · entry 1 MARTIN WILLIAM E. III · CIK 0001949513 · President Multiomics 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,062 F1 · shares: Grant of restricted stock units to the Reporting Person under the Company's Equity Incentive Plan. No amount was paid upon grant of the units. Because the units are payable solely in shares of common stock, they are reported in Table I of this Form 4. The units are subject to time-based vesting and will vest 50% per year, beginning on September 14, 2027, subject to the terms of the award agreement. Read SEC document |
| April 28, 2026 Filed Apr 30, 2026 20:15 UTC | Azenta, Inc. AZTA · Entity 4724 | GrantCommon | 17,790 | $24.24 | $431,229.60 |
DisclosureSEC source: 0001949513-26-000008 · ownership.xml · nonDerivative · entry 1 MARTIN WILLIAM E. III · CIK 0001949513 · President Multiomics 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,790 F1 · shares: Grant of restricted stock units to the Reporting Person under the Company's Equity Incentive Plan. No amount was paid upon grant of the units. The units will vest over three years, 33% on Apriil 18, 2027, 33% on Apriil 18, 2028, and 33% on Apriil 18, 2029. Read SEC document |
| March 17, 2025 Filed Mar 19, 2025 21:57 UTC | MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291 | GrantClass A Common Stock | 986,194 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001823239-25-000052 · wk-form4_1742421463.xml · nonDerivative · entry 1 MARTIN WILLIAM E. III · CIK 0001949513 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,814,643 F1 · price: Represents restricted stock units ("RSUs") awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan. Each RSU represents the right to receive one share of Class A Common Stock of the Issuer upon vesting. The RSUs will vest in 1/3rd increments on each of March 15, 2026, March 15, 2027, and March 15, 2028, subject to the Reporting Person's continued employment with the Issuer. Read SEC document |
| January 15, 2025 Filed Jan 17, 2025 21:19 UTC | MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291 | Tax withholdingClass A Common Stock | 160,981 | $4.56 | $734,073.36 |
DisclosureSEC source: 0001823239-25-000016 · wk-form4_1737148764.xml · nonDerivative · entry 1 MARTIN WILLIAM E. III · CIK 0001949513 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 828,449 F1 · shares: Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of restricted stock unit awards held by the reporting person. Read SEC document |
| October 15, 2024 Filed Oct 16, 2024 20:26 UTC | MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291 | Tax withholdingClass A Common Stock | 50,843 | $8.29 | $421,488.47 |
DisclosureSEC source: 0001823239-24-000102 · wk-form4_1729110408.xml · nonDerivative · entry 1 MARTIN WILLIAM E. III · CIK 0001949513 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 989,430 F1 · shares: Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of restricted stock unit awards held by the reporting person. Read SEC document |
| January 16, 2024 Filed Jan 18, 2024 23:30 UTC | MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291 | GrantClass A Common Stock | 758,415 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001823239-24-000016 · wk-form4_1705620637.xml · nonDerivative · entry 1 MARTIN WILLIAM E. III · CIK 0001949513 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,040,273 F1 · price: Represents restricted stock units ("RSUs") awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan. Each RSU represents the right to receive one share of Class A Common Stock of the Issuer upon vesting. The RSUs will vest in one-half (1/2) increments on each of January 15, 2025, and January 15, 2026, subject to the Reporting Person's continued employment with the Issuer. Read SEC document |
| October 16, 2023 Filed Oct 17, 2023 21:12 UTC | MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291 | Tax withholdingClass A Common Stock | 66,197 | $7.54 | $499,125.38 |
DisclosureSEC source: 0001823239-23-000085 · wk-form4_1697577134.xml · nonDerivative · entry 1 MARTIN WILLIAM E. III · CIK 0001949513 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 281,858 F1 · shares: Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of restricted stock unit awards held by the reporting person. Read SEC document |
| August 21, 2023 Filed Aug 22, 2023 20:22 UTC | MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291 | GrantPerformance Stock Units · Derivative | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001823239-23-000083 · wf-form4_169273574241776.xml · derivative · entry 1 MARTIN WILLIAM E. III · CIK 0001949513 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Class A Common Stock · 300,000 shares Expires 2026-08-21 F1 · derivative.exercise_price: Represents performance-based restricted stock units ("PSUs") awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan (the "Omnibus Incentive Plan"). Each PSU represents the contingent right to receive one share of Class A Common Stock of the Issuer. The PSUs will vest on August 21, 2026, if and to the extent the volume-weighted average price of a share of the Class A Common Stock of the Issuer equals or exceeds certain thresholds for the 60 consecutive trading days immediately preceding August 21, 2026, provided that in the event of a Change in Control (as defined in the Omnibus Incentive Plan) prior to August 21, 2026, the PSUs will convert to time-based restricted stock units that will fully vest on August 21, 2026, subject to the Reporting Person's continued employment with the Issuer through such date. F1 · derivative.exercise_date: Represents performance-based restricted stock units ("PSUs") awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan (the "Omnibus Incentive Plan"). Each PSU represents the contingent right to receive one share of Class A Common Stock of the Issuer. The PSUs will vest on August 21, 2026, if and to the extent the volume-weighted average price of a share of the Class A Common Stock of the Issuer equals or exceeds certain thresholds for the 60 consecutive trading days immediately preceding August 21, 2026, provided that in the event of a Change in Control (as defined in the Omnibus Incentive Plan) prior to August 21, 2026, the PSUs will convert to time-based restricted stock units that will fully vest on August 21, 2026, subject to the Reporting Person's continued employment with the Issuer through such date. Read SEC document |
| October 17, 2022 Filed Oct 19, 2022 20:39 UTC | MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291 | GrantPerformance Stock Units · Derivative | 240,038 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-033827 · doc4.xml · derivative · entry 4 MARTIN WILLIAM E. III · CIK 0001949513 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,038 Underlying: Class A Common Stock · 240,038 shares Expires 2025-10-17 F4 · derivative.exercise_price: Represents performance stock units ("PSUs") awarded under the Omnibus Incentive Plan. Each PSU represents the contingent right to receive one share of Class A Common Stock of the Issuer. The PSUs will vest on October 17, 2025, if and to the extent the 60-trading day volume-weighted average stock price of the Class A Common Stock of the Issuer equals or exceeds certain thresholds, provided that in the event of a Change in Control (as defined in the Omnibus Incentive Plan) prior to October 17, 2025, the PSUs will convert to time-based RSUs that will fully vest on October 17, 2025, subject to the Reporting Person's continued employment with the Issuer. F4 · derivative.exercise_date: Represents performance stock units ("PSUs") awarded under the Omnibus Incentive Plan. Each PSU represents the contingent right to receive one share of Class A Common Stock of the Issuer. The PSUs will vest on October 17, 2025, if and to the extent the 60-trading day volume-weighted average stock price of the Class A Common Stock of the Issuer equals or exceeds certain thresholds, provided that in the event of a Change in Control (as defined in the Omnibus Incentive Plan) prior to October 17, 2025, the PSUs will convert to time-based RSUs that will fully vest on October 17, 2025, subject to the Reporting Person's continued employment with the Issuer. Read SEC document |
| October 17, 2022 Filed Oct 19, 2022 20:39 UTC | MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291 | GrantEmployee Stock Option (Right to Buy) · Derivative | 403,946 | $0.00 Strike: $19.42 | $0.00 |
DisclosureSEC source: 0000899243-22-033827 · doc4.xml · derivative · entry 3 MARTIN WILLIAM E. III · CIK 0001949513 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 403,946 Underlying: Class A Common Stock · 403,946 shares Expires 2032-10-17 F3 · derivative.exercise_date: Represents options awarded under the Omnibus Incentive Plan. These options will vest 25% on October 17, 2023 and in near-equal 1/36th installments each month thereafter, subject to the Reporting Person's continued employment with the Issuer. Read SEC document |
| October 17, 2022 Filed Oct 19, 2022 20:39 UTC | MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291 | GrantClass A Common Stock | 228,036 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-033827 · doc4.xml · nonDerivative · entry 2 MARTIN WILLIAM E. III · CIK 0001949513 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 348,055 F2 · price: Represents RSUs awarded under the Omnibus Incentive Plan. Each RSU represents the right to receive one share of Class A Common Stock of the Issuer upon vesting, subject to the Reporting Person's continued employment with the Issuer. The RSUs will vest in 1/3rd increments on each of October 17, 2023, October 17, 2024, and October 17, 2025, subject to the Reporting Person's continued employment with the Issuer. Read SEC document |
| October 17, 2022 Filed Oct 19, 2022 20:39 UTC | MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291 | GrantClass A Common Stock | 120,019 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-033827 · doc4.xml · nonDerivative · entry 1 MARTIN WILLIAM E. III · CIK 0001949513 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,019 F1 · price: Represents restricted stock units ("RSUs") awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan (the "Omnibus Incentive Plan"). Each RSU represents the right to receive one share of Class A Common Stock of the Issuer upon vesting, subject to the Reporting Person's continued employment with the Issuer. The RSUs will vest 50% on each of October 17, 2023 and October 17, 2024, subject to the Reporting Person's continued employment with the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.